Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Impilo on the establishment of a continuation fund
Mandate

Vinge advises Impilo on the establishment of a continuation fund

November 15, 2024

Vinge has advised Impilo with regulatory advice on the establishment of Impilo Orphan Drugs, a so-called continuation fund. The continuation fund will have EUR 320m in commitments and will invest in Immedica, in which KKR recently became an owner alongside Impilo.

Impilo is a Nordic investment company specializing in investments within the pharmaceutical, medical technology, healthcare services and other health-related industries. Impilo holds a highly diversified portfolio of healthcare investments and manages approximately EUR 1 billion in capital, from leading Nordic and international investors.

Vinges team consisted of Nils Unckel, Anton Sjökvist and Viktoria Wnuk.

Related

Vinge advises L5 Navigation in connection with the acquisition of Lundaman Instrument

 L5 Navigation Systems AB has acquired the shares in Lundaman Instrument AB. Lundaman develops and supplies weighing systems for wheel loaders and forklift trucks, focusing on the construction, recycling, industrial and materials handling sectors.
May 13, 2026

Vinge advises Aonic in connection with the issuance of subsequent senior secured bonds of EUR 25 million

 Vinge has advised Aonic AB (publ) in connection with the issuance of subsequent senior secured bonds of EUR 25 million, and parallel written procedure to increase the bond framework to EUR 150 million.
May 12, 2026

Vinge advises Consolid Equity and other sellers on the sale of Sertion to Altor

 Vinge has advised Consolid Equity and other sellers on the sale of the Sertion Group to Altor. In connection with the transaction, entrepreneurs and management will reinvest and remain as key owners, partnering with Altor to accelerate the group’s next phase of growth across existing markets and into new geographies.
May 11, 2026